Use of polymyxin B in patients with renal impairment: A retrospective examination of 5&nbsp;cases

Yu,Meiling; Zou,Qi; Wang,Huaxue; Zheng,Shengyong; Xu,Jian; Deng,Ximing; Liu,Chen; Zhao,Shibing; He,Xiandi; Wu,Qiang

doi:10.3892/etm.2020.9217

Use of polymyxin B in patients with renal impairment: A retrospective examination of 5 cases

Authors:
- Meiling Yu
- Qi Zou
- Huaxue Wang
- Shengyong Zheng
- Jian Xu
- Ximing Deng
- Chen Liu
- Shibing Zhao
- Xiandi He
- Qiang Wu
View Affiliations

Affiliations: Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Published online on: September 11, 2020 https://doi.org/10.3892/etm.2020.9217
Article Number: 89
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to provide an idea dose of polymyxin B in Chinese patients with renal impairment, the present study collected the clinical data of all patients with renal impairment who received polymyxin B therapy in the intensive care unit (ICU) of The First Affiliated Hospital of Bengbu Medical College (Bengbu, China). The clinical data of six patients treated in the ICU between February 2018 and May 2019 were retrospectively analyzed. All patients had renal impairment and were treated with polymyxin B combination therapy. The patients in the current study received polymyxin B and carbapenem, or polymyxin, carbapenem, cefoperazon and sulbactam, or polymyxin B, carbapenems and aminoglycoside treatment. One patient discontinued treatment. The other five patients received polymyxin B at a dosage of 50 mg every 12 h (100 mg/day) through an intravenous drip. During treatment, four of the five patients had deteriorating renal function to varying degrees, and continuous renal replacement therapy (CRRT) was initiated. Polymyxin B was discontinued in all patients when the infection was controlled. After treatment, four of five patients showed improvement in renal function, and had normal kidney function at the 1‑month follow‑up evaluation, whereas one patient had chronic renal disease. During hospitalization, one patient experienced neurotoxicity, showing decreased limb muscle strength and cognitive impairment, which might have been caused by polymyxin B, according to the Naranjo adverse drug reactions probability scale (also known as the Naranjo algorithm) score. The present report demonstrated that the administration of 100 mg daily dosage of polymyxin B to the five patients weighing between 50 and 75 kg, could control pulmonary infection during the course of treatment of Chinese patients with renal impairment, however, further research is needed to verify this result. Risk factors for nephrotoxicity and neurotoxicity need to be fully assessed before initiating polymyxin B therapy in patients with renal impairment.

View Figures

View References

1	Zakuan ZD and Suresh K: Rational use of intravenous polymyxin B and colistin: A review. Med J Malaysia. 73:351–359. 2018.PubMed/NCBI
2	Wang M, Wei H, Zhao Y, Shang L, Di L, Lyu C and Liu J: Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China. Bosn J Basic Med Sci. 19:86–93. 2019.PubMed/NCBI View Article : Google Scholar
3	Mao T, Zhai H, Duan G and Yang H: Patterns of drug-resistant bacteria in a general hospital, China, 2011-2016. Pol J Microbiol. 68:225–232. 2019.PubMed/NCBI View Article : Google Scholar
4	Yue D, Song C, Zhang B, Liu Z, Chai J, Luo Y and Wu H: Hospital-wide comparison of health care-associated infection among 8 intensive care units: A retrospective analysis for 2010-2015. Am J Infect Control. 45:e7–e13. 2017.PubMed/NCBI View Article : Google Scholar
5	Xu A, Zheng B, Xu YC, Huang ZG, Zhong NS and Zhuo C: National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect. 22 (Suppl 1):S1–S8. 2016.PubMed/NCBI View Article : Google Scholar
6	Rigatto MH, Falci DR and Zavascki AP: Clinical use of polymyxin B. Adv Exp Med Biol. 1145:197–218. 2019.PubMed/NCBI View Article : Google Scholar
7	De León-Borrás R, Sánchez-Sergentón C, Mayor-Becerra A and Laureano-Cuadrado AF: Polymyxin B for negative multidrug resistant bacteria in a Hispanic population. P R Health Sci J. 38:15–21. 2019.PubMed/NCBI
8	Liang Q, Huang M and Xu Z: Early use of polymyxin B reduces the mortality of carbapenem-resistant klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 23:60–65. 2019.PubMed/NCBI View Article : Google Scholar
9	Onufrak NJ, Rao GG, Forrest A, Pogue JM, Scheetz MH, Nation RL, Li J and Kaye KS: Critical need for clarity in polymyxin B dosing. Antimicrob Agents Chemother. 61:e00208–e00217. 2017.PubMed/NCBI View Article : Google Scholar
10	Elias LS, Konzen D, Krebs JM and Zavascki AP: The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 65:2231–2237. 2010.PubMed/NCBI View Article : Google Scholar
11	Rigatto MH, Falci DR, Lopes NT and Zavascki AP: Clinical features and mortality of patients Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. Int J Antimicrob Agents. 47:146–150. 2016.PubMed/NCBI View Article : Google Scholar
12	Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS and Tam VH: Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 104:534–538. 2018.PubMed/NCBI View Article : Google Scholar
13	Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, et al: Population pharmacokinetics of intravenous polymyxin B inpatients: Implications for selection of dosage regimens. Clin Infect Dis. 57:524–531. 2013.PubMed/NCBI View Article : Google Scholar
14	Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP and Scheetz MH: Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. 62:e01475–17. 2018.PubMed/NCBI View Article : Google Scholar
15	Abdelraouf K, He J, Ledesma KR, Hu M and Tam VH: Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 56:5724–5727. 2012.PubMed/NCBI View Article : Google Scholar
16	Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ and Li J: Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: Are we there yet? Int J Antimicrob Agents. 48:592–597. 2016.PubMed/NCBI View Article : Google Scholar
17	Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, et al: International Consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 39:10–39. 2019.PubMed/NCBI View Article : Google Scholar
18	Satlin MJ, Jenkins SG and Walsh TJ: The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 58:1274–1283. 2014.PubMed/NCBI View Article : Google Scholar
19	Bassetti M, Peghin M and Pecori D: The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 29:583–594. 2016.PubMed/NCBI View Article : Google Scholar
20	Justo JA and Bosso JA: Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 35:28–33. 2015.PubMed/NCBI View Article : Google Scholar
21	Falagas ME and Kasiakou SK: Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care. 10(R27)2006.PubMed/NCBI View Article : Google Scholar
22	Arulappen AL, Danial M and Sulaiman SAS: Evaluation of reported adverse drug reactions in antibiotic usage: A retrospective study from a tertiary care hospital, Malaysia. Front Pharmacol. 9(809)2018.PubMed/NCBI View Article : Google Scholar
23	Gupta SK and Kumar KD: An assessment of reported adverse drug reactions in a Tertiary Care Hospital in South India: A retrospective cross-sectional study. Int J Pharm Investig. 7:193–197. 2017.PubMed/NCBI View Article : Google Scholar
24	Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL and Zavascki AP: Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methane sulfonate sodium. Int J Antimicrob Agents. 43:349–352. 2014.PubMed/NCBI View Article : Google Scholar
25	Zhang H, Wang R, Shu W, Tang R, Liang X, Zhang J and Wu J: Monitoring of vancomycin serum concentrations and the evaluation of its safety and treatment outcomes in adult patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 30:538–543. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
26	Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, Lovering AM and Wiffen PJ: (BSAC Working Party on Therapeutic Drug Monitoring). Amikacin use and therapeutic drug monitoring in adults: Do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 71:2754–2759. 2016.PubMed/NCBI View Article : Google Scholar
27	Zhu H, Guo SC, Liu ZQ, Wang B, Fu L, Chu NH and Lu Y: Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. Int J Tuberc Lung Dis. 22:931–936. 2018.PubMed/NCBI View Article : Google Scholar